Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) Stock Price & Analysis
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) — price $1.88 (0.00%), as of the Nov 19, 2026 trading session; market cap $7.06B.
Educational signal · not a buy or sell recommendation · How to read this
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. · SFOSF
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive Chinese healthcare enterprise engaged in pharmaceutical R&D, manufacturing, and sales, alongside medical devices, diagnostics, and healthcare services. The company focuses on critical therapeutic areas such as oncology and metabolic disorders, operating across Mainland China and international markets.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.88 | |
| Change on the day | 0.00% | |
| 52-week range | $1.88 – $3.30 | |
| Market capitalisation | $7.06B | — |
| Price / earnings (trailing) | 15.51 | |
| Shares traded on the day | 8 |
Price & events
Other perspectives
Council score for Shanghai Fosun Pharmaceutical (Group) Co. (SFOSF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Jun 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Jun 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Shanghai Fosun Pharmaceutical (Group) Co. (SFOSF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) is the company analyzed here. It employs 40,603 people and is led by Yi Liu. In Q3 FY2026 it reported revenue of CN¥10.02B and net income of CN¥946M. The market values it at $7.06B.
What do the latest results show for Shanghai Fosun Pharmaceutical (Group) Co. (SFOSF)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of CN¥10.02B. Against analyst estimates the company has EPS beat 6 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | CN¥10.02B | CN¥946M | CN¥0.36 (diluted) |
| Q2 FY2026 | CN¥20.10B | CN¥1.70B | CN¥0.65 (diluted) |
| Q1 FY2026 | CN¥10.07B | CN¥871M | CN¥0.33 (diluted) |
| Q4 FY2025 | CN¥21.71B | CN¥1.64B | CN¥0.62 (diluted) |
What are the financial strengths and risks for Shanghai Fosun Pharmaceutical (Group) Co. (SFOSF)?
Short answer · as of
The distress and quality screens read Altman Z 1.32 · Piotroski F 8. Trailing ratios: ROE 7.1% · ROA 2.8% · current ratio 0.98 · earnings yield 5.7% · free-cash-flow yield 0.6%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SFOSF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SFOSF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Shanghai Fosun Pharmaceutical (Group) Co. (SFOSF)?
Shanghai Fosun Pharmaceutical (Group) Co. Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the SFOSF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is SFOSF a good stock to buy?
Stock Expert AI does not rate SFOSF buy, sell or hold. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SFOSF stock price today?
The last price recorded for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does Shanghai Fosun Pharmaceutical (Group) Co., Ltd. navigate the complex regulatory environment in China and internationally?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. navigates the complex regulatory environment by maintaining a diversified portfolio and focusing on compliance across its operational segments. Its established presence and experience in the domestic market likely provide insights into these changes.
What are the key factors to evaluate for SFOSF?
Evaluate SFOSF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Fosun Pharma's involvement in this area allows it to diversify its revenue streams beyond pharmaceuticals. Not financial advice.
How frequently does SFOSF data refresh on this page?
SFOSF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SFOSF's recent stock price performance?
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence and diversified operations across pharmaceutical manufacturing, medical devices, healthcare services, and distribution. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SFOSF overvalued or undervalued right now?
The trailing P/E of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SFOSF before investing?
Before investing in Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SFOSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 8 from Financial Modeling Prep (FMP) and 7 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com